Johns Hopkins Medicine Johns Hopkins Logo
make a gift
hopkins urology on you tube  twitter urology department at hopkins   facebook urology department at hopkins  blog urology department at hopkins  
Fisher Biomarker Research Laboratory
VELTRI – (43 contributions with Partin): KEY UROLOGY CONTRIBUTIONS: 1994-
  1. Veltri, R.W., Partin AW, Epstein JI, Marley GM, Miller MC, et al.  Quantitative Nuclear Morphometry, Markovian Texture Descriptors, and DNA content Captured on a CAS-200 Image Analysis System, Combined with PCNA and Her-2/neu Immunohistochemistry for Prediction of Prostate Cancer Progression.  J. Cellular Biochemistry, Suppl. 19: 249-258, 1994.
  2. Hu, Y., K. Ashenayi, Veltri, R.W, R. Hurst, and R. Bonner. Neural Network Based Bladder Cancer Cell Classification. Proceedings of World Congress on Neural Networks, San Diego. Volume 1: 416-21, 1994.
  3. Bostwick DG, Burke HB, Wheeler TM, Chung LW, Bookstein R, Pretlow TG, Nagle RB, Montironi R, Lieber MM, Veltri RW, et al.  The most promising surrogate endpoint biomarkers for screening candidate chemopreventive compounds for prostatic adenocarcinoma in short-term phase II clinical trials.  J Cell Biochem Suppl, 19:283-289, 1994.
  4. Ostrander GK, Blair JB, Stark BA, Marley GM, Bales WD, Veltri RW, Hinton DE, Okihiro M, Ortego LS, Hawkins WE.  Long-term primary culture of epithelial cells from rainbow trout (Oncorhynchus mykiss) liver. In Vitro Cell Dev Biol Anim, May;31(5):367-78, 1995.
  5. Carmichael, M.J., Veltri RW, Partin AW, Miller MC, Walsh PC, Epstein JI.  Deoxyribonucleic Acid Ploidy Analysis as a Predictor of Recurrence Following Radical Prostatectomy for Stage T2 Disease.  J. Urology 153: 1015-1019, 1995.
  6. Berges, RR, Vukanovic J Epstein JI, Carmichael, Cisek ML, Johnson DE, Veltri RW, Walsh PC, and Isaacs JT. Implication of cell kinetic changes during the progression of human prostatic cancer. Clin Cancer Res 1: 473-480, 1995.
  7. McCue PA, Gomella LG, Veltri RW, Marley GM, Miller MC, Lattime EC.  Development of secondary structure, growth characteristics and cytogenetic analysis of human transitional cell carcinoma xenografts in scid/scid mice.  J Urol, Mar;155(3):1128-32, 1996.
  8. Veltri RW and Holzman D.  News article:  Algorithms vie for diagnostic role in prostate cancer.  JNCI  89(1): 1-4;15, 1997.
  9. An G, Luo G, Veltri RW, O'Hara SM.  Sensitive, nonradioactive differential display method using chemiluminescent detection.  Biotechniques, Mar;20(3):342-4, 346, 1996.
  10. Badalament, RA, Miller MC, Peller PA, Young DC, Bahn DK, Kochie P, O’Dowd GJ, and Veltri RW.  An Algorithm for Predicting Non-organ Confined Prostate Cancer Using the Results Obtained From Sextant Core Biopsies and Prostate Specific Antigen Level.  J. Urology 156: 1375-80, 1996.
  11. Veltri, RW, Miller MC, Partin AW, Coffey DS, and Epstein JI.  Ability to Predict Biochemical Progression Using Gleason Score and Computer-Generated Quantitative Nuclear Grade Derived from Cancer Cell Nuclei.  Urology 48: 685-91, 1996.
  12. Hurst RE, Roy JB, Kim KW, Veltri RW, Marley GM, Patton KP, Schackelford DL, Stein PL, and Parsons CL.  A Deficit of Chondroitin Sulfate Proteoglycans on Bladder Uroepithelium in Interstitial Cystitis.  Urology  48: 817-821, 1996.
  13. Marley, G.M., Miller MC, Kattan MC, Zhao G, Patton KP, Vessella RL, Wright Jr. GL, Schellhammer PF, and Veltri RW.  Free and Complexed Prostate Specific Antigen Serum Ratios to Predict Probability of Primary Prostate Cancer and Benign Prostatic Hyperplasia.  Urology 48(6A): 16-22, 1996.
  14. Weinstein, MH, Partin AW, Veltri RW, and Epstein JI. Neuroendocrine Differentiation in Prostate cancer.  Enhanced Prediction of Progression after Radical Prostatectomy.  Human Pathology 27: 683-87, 1996.
  15. von Eschenbach AC, Brawer MK, di Sant’Agnese PA, Humphrey PA, Mahran H, Murphy GP, Sebo TJ, Veltri RW. Exploration of new pathologic factors in terms of potential for prognostic significance and future applications. Cancer 78: 372-375, 1996.
  16. Veltri RW and Holzman D.  News article:  Algorithms vie for diagnostic role in prostate cancer.  JNCI  89(1): 1-4;15, 1997.
  17. Moreno JG, O'Hara SM, Long JP, Veltri RW, Ning X, Alexander AA, Gomella LG.  Transrectal ultrasound-guided biopsy causes hematogenous dissemination of prostate cells as determined by RT-PCR.  Urology  Apr;49:515-20, 1997.
  18. Hurst RE, Bonner RB, Ashenayi K, Veltri RW, and Hemstreet III GP.  Neural Net-based identification of cells expressing the p300 tumor-related antigen using fluorescence image analysis.  Cytometry  27: 36-42, 1997.
  19. O’Dowd, GJ. Veltri RW, Orozco R, Miller MC, Osterling LP.  Update on the Appropriate Staging Evaluation for Newly Diagnosed Prostate Cancer.  J. Urology 158: 687-698, 1997
  20. Silberman, MA, Partin AW, Veltri RW, and Epstein JI. Tumor Angiogenesis Correlates with Progression after Radical Prostatectomy but Not with Pathologic Stage in Gleason Sum 5 to 7 Adenocarcinoma of the prostate.  Cancer 79:772-79, 1997.
  21. Slaton, JW, Dinney CPN, Veltri RW, Miller MC, Leibert M, O’Dowd GJ, and Grossman HB. DNA Ploidy enhances the cytologic prediction of Recurrent Transitional Cell Carcinoma of the Bladder.  J. Urology, 158: 806-811, 1997.
  22. Dinney CPN, Babkowski RC, Anteolo M, Perrotte P Liebert M, Zhuang H-Z, Palmer J, Veltri RW,  Katz R, and Grossman B. Relationship among cystectomy, microvessel density and prognosis in stage T1 transitional cell carcinoma of the bladder. J Urology 1998; 160: 1285-90.
  23. Orozco, R. O’Dowd GJ, Kunnel B, Miller MC, RW Veltri, Observations of Pathology Trends in 62,537 Prostate Biopsies Obtained from Urology Private Practices in the United States. Urology, 51: 186-195, 1998.
  24. Veltri, RW, O’Dowd GJ, Orozco R, Miller MC. The Role of Biopsy Pathology, Quantitative Nuclear Morphometry, and Biomarkers in the Pre-operative Prediction of Prostate Cancer Staging and Prognosis.  Seminars in Urologic Oncology, 16(3): 106-107, 1998.
  25. Wojcik, EM, Miller MC, O’Dowd GJ, Veltri RW, The Value of Computer Assisted Quantitative Nuclear Grading in Differentiation of Normal Urothelial Cells from Low and High Grade Transitional Cell Carcinomas.  Analytical and Quantitative Cytology and Histology, 20: 69-76, 1998.
  26. Wojcik, EM, Miller MC, Wright BC, RW Veltri, O’Dowd GJ. Comparative Analysis of DNA Content in Polyoma virus-Infected Urothelial Cells, Urothelial Dysplasia and High Grade Transitional Cell Carcinoma.  Analytical and Quantitative Cytology and Histology, 19: 430-436, 1997.
  27. Veltri RW, Miller MC, Zhao G, Ng AY, Marley GM, Wright GL, Vessella RL, and Ralph DA.  Interleukin-8 (IL-8) serum levels in patients with benign prostatic hyperplasia and prostate cancer.  Urology  53: 139-47, 1999.
  28. An G, Cazares L, Luo G, Miller MC, Wright GL, and Veltri RW.  Differential expression of full length and a truncated Her-2/neu oncogene receptor in prostate cancer assessed using relative quantitative RT-PCR.  Mol Urol  2: 305-310, 1999.
  29. Veltri RW and Miller MC.  Free/Total PSA Ratios improve differentiation of benign and malignant disease of the prostate: Critical Analysis of two different test populations.  Urology 53(4): 736-45, 1999.
  30. Ng A, Bales WD, and Veltri RW.  Phenylbutyrate induced apoptosis and differential expression of BCL-2, BAX, p53, and FAS in human Prostate Cancer Cell Lines.  Analytical and Quantitative Cytology and Histology 22(1): 45-54, 2000.
  31. An G, Meka RCS, Bright SP, and Veltri RW.  Human prostate specific transglutaminase (pTGase) gene: Promoter cloning, tissue specific expression and down regulation in metastatic prostate cancer (CaP).  Urology 54: 1105-1111, 1999.
  32. Potter, SR, Miller MC, Mangold LA, Jones KA, Epstein JI, Veltri RW and Partin AW.  Genetically engineered neural networks for predicting prostate cancer progression after radical prostatectomy.  Urology 54: 791-795, 1999.
  33. Reckwitz T, Potter SR, Snow PB, Zhang Z, Veltri RW, and Partin AW.  Artificial neural networks in urology: Update 2000.  Prostate Cancer & Prostatic Diseases 2: 222-226, 1999.
  34. An Gang, Ng AY, Meka CSR, Luo G, Bright SP, Cazares L, Wright GL, and Veltri RW.  Cloning and characterization of UROC28, a novel gene overexpressed in prostate, breast and bladder cancers. Cancer Research 60: 7014-7020, 2000.
  35. O’Dowd, GJ, MC Miller, R Orozco, and RW Veltri.  Analysis of repeat biopsy results within one year following a non-cancer diagnosis.  Urology 55 (4):553-59, 2000.
  36. Marks LS, Partin AW, Epstein JI, Tyler VE, Simon I, Macairan ML, Chan TL, Dorey FJ, Garris JB, Veltri RW, Santos PBC, Stonebrook KA, and DeKernion JB.  Effects of a saw palmetto herbal blend in men with symptomatic benign prostatic hyperplasia.  J Urol  163(5): 1451-1456, 2000.
  37. Veltri RW, Miller MC, and An G.  Standardization, analytical validation, and quality control of intermediate endpoint biomarkers.  Urology  57(Suppl 4A), 164-70, 2001. 
  38. Veltri, RW, Partin, AW, and Miller, MC.  Quantitative nuclear grade (QNG): A new image analysis-based biomarker of clinically relevant nuclear structure alterations.  J. Cellular Biochemistry, 35: (Suppl), 151-157, 2000.
  39. O’Dowd GJ, Veltri RW, Miller MC, and Strum SB. The Gleason Score: A Significant Biologic Manifestation of Prostate Cancer Aggressiveness on Biopsy.  PCRI Insights, vol. 4, January, 2001.
  40. Veltri, RW, Miller MC, Partin, AW, Poole Ed, and O’Dowd GJ.  Prediction of prostate cancer stage using quantitative biopsy pathology. Cancer 91: 2322-2328, 2001.
  41. Prescott JL, Montie J, Pugh TW, McHugh T, and Veltri RW.  Clinical sensitivity of p53 mutation detection in matched bladder tumor, bladder wash, and voided urine specimens.  Cancer 91: 2127-2135, 2001.
  42. Miller MC, O’Dowd GJ, Partin AW, and Veltri RW.  Contemporary use of complexed PSA and calculated Free PSA for Early Detection of Prostate Cancer: Impact of Changing Disease Demographics.  Urology 57: 1105-1111, 2001.
  43. Veltri RW, Miller MC, Mangold LA, O'Dowd GJ, Epstein JI, Partin AWPrediction of pathological stage in patients with clinical stage T1c prostate cancer: the new challenge.  J Urol 168(1):100-4, 2002.
  44. An G and Veltri. RW  Differential display polymerase chain reaction using chemiluminescent detection.  In: Luminescence Biotechnology.  Eds. Knox Van Dyke, Christopher Van Dyke, and Karen Woodfork. CRC Press (Boca Raton, New York, and Washington, DC), 2002. 
  45. Veltri RW, Ph.D., M. Craig Miller. B.S., Gerard J. O’Dowd. M.D., and Alan W. Partin, M.D., Ph.D.  Impact of Age on Total and Complexed PSA Cutoffs in a Contemporary Referral Series of Men with Prostate Cancer.  Urology 60 (Suppl 4A): 47-52, 2002.
  46. Veltri, RW, Marks LS, Miller MC, Bales WD, Fan J, MaCairan ML, Epstein JI, and Partin AW.  Saw Palmetto Alters Nuclear Measurements Reflecting DNA Content In Men With Symptomatic BPH: Evidence For A Possible Molecular Mechanism.  Urology 60: 617-22, 2002.
  47. Sawczuk IS, Pickens CL, Vasa UR,  Ralph DA, Ph.D., Norris KA, Miller MC, Ng AY, Grossman HB, and Veltri RW. DD23 Biomarker: A Prospective Clinical Assessment In Routine Urinary Cytology Specimens From Patients Being Monitored For TCC.  Urologic Oncology  7: 185-190, 2002.
  48. Gilbert SM, A Shabsigh, Sawczuk A, U Vasa, Angela Ng, C Pickens, K Norris, S Bright, GJ O’Dowd, MC Benson, CA Olsson, AS Sawczuk and RW Veltri,. Evaluation of DD23 as a marker for detection of recurrent transitional cell carcinoma (TCC) of the bladder in patients with a history of bladder cancer.  Urology  61: 539-543, 2003.
  49. Veltri, RW. , Manisha C, Miller MC, Poole EC, O’Dowd GJ and Partin AW.  Comparison of Logistic Regression and Neural Net Modeling for Prediction of Prostate Cancer Pathologic Stage.  Clin Chem. 48(10): 1828-34, 2002.
  50. Ellison LE, Cheli C, Bright S, Veltri RW, and Partin AW.  Cost-benefit analysis of total PSA, Free/Total PSA and complexed PSA for prostate cancer screening.  Urology 60 (Suppl 4A): 42-46, 2002.
  51. Haese A, Chaudhari M, Miller MC, Epstein JI, Graefen M, Hammerer P, Palisaar J, Huland H, Poole EC, O’Dowd GJ, Partin AW, and Veltri RW.  Quantitative biopsy pathology for the prediction of pathologically organ confined prostate cancer: A multi-institutional validation study.  Cancer 97: 969-78,  2003.
  52. Presti JC, O’Dowd GJ, Miller MC, Mattu R, and Veltri RW.  Extended peripheral zone biopsy schemes increase cancer detection rates and minimize variance in PSA and age-related cancer rates – results of a community multipartite study.  J Urology 169: 125-129, 2003.
  53. Gretzer MB, Partin AW, Chan DW, and Veltri RW.  Modern Tumor Marker Discovery in Urology: Surface Enhanced Laser Desorption and Ionization (SELDI). Reviews in Urology, 5(2): 81-89, 2003.
  54. Khan MA, Partin AW, Rittenhouse HG, Mikolajczyk SD, Sokoll LJ, Chan DW, and Veltri RW. Evaluation of Pro-PSA for the Early Detection of Prostate Cancer in Men with a total PSA Range of 4.0-10 ng/ml. J Urology  170: 723 -726, 2003.
  55. Khan MA, H. Carter HB, Epstein JI, Miller MC, Landis P, Walsh PC, Partin AW and Veltri RW. Can PSA derivatives and pathological parameters predict significant change in expectant management criteria for men with prostate cancer? J Urology 170: 2274-78, 2003.
  56. Khan MA, Walsh PC, Miller MC, Bales WD, Epstein JI, Mangold LA, Partin AW and Veltri RW. Quantitative alterations in nuclear structure predict prostate cancer distant metastasis and death in men with biochemical recurrence post-radical prostatectomy. Cancer, 98: 2583-9, 2003.
  57. Park J, Sokoll LJ, Bruzek DJ, Mangold LA, Gurganus R, Khan MA, Partin AW, Chan DW, and Veltri RW. Comparison of total PSA and derivative levels in a screening population of African-American, Caucasian, and Korean-American men. Clinical Prostate Cancer, 2: 173-76, 2004.
  58. Veltri RW, Khan MA, Miller MC, Epstein JI, Mangold LA, Walsh PC, Partin AW. Ability to predict metastasis based on pathology findings and alterations in nuclear structure of normal-appearing and cancer peripheral zone epithelium in the prostate.  Clin Cancer Res., 10(10): 3465-73, 2004.
  59. Veltri RW, Partin AW, and Miller MC. Quantitative Nuclear Grade (QNG): The clinical applications of the quantitative measurement of nuclear structure using image analysis. In: Cancer Drug Discovery and Development. Gary J. Kelloff, Ernest T. Hawk and Caroline C. Sigman, Eds. The Humana Press Inc., Totowa, NJ, Volume 2, Chapter 6, 97-108, 2005.
  60. Gretzer MB, Chan DW, van Rootselaar CL, Rosenzweig JM, Dalrymple S, Mangold LA, Partin AW, and Veltri RW.  Proteomic analysis of Dunning Prostate Cancer Cell Lines with Variable Metastatic Potential using SELDI-TOF. Prostate. 60:(4):325-31, 2004.
  61. Veltri, RW, Jae Park, M.C. Miller, Leonard S. Marks, Munekado Kojima, Cameron van Rootselaar, Masood A. Khan, and Alan W. Partin. Stromal-Epithelial Measurements of Prostate Cancer in Native Japanese and Japanese-American Men.  Prostate Cancer Prostatic Dis. 7(3):232-7, 2004.
  62. Marks LS, Kojima M, Demarzo A, Heber D, Bostwick DG, Qian J, Dorey FJ, Veltri RW, Mohler JL, Partin AW.  Prostate cancer in native Japanese and Japanese-American men: Effects of dietary differences on prostatic tissue. Urology, 64(4):765-71, 2004.
  63. Rogers CG, MA Khan, MC Miller, RW Veltri, and AW Partin. Natural history of progression in patients who fail to achieve an undetectable PSA following radical prostatectomy. Cancer, 2004; 101:2549–56.
  64. Bast RC, Jr., Hans Lilja, N Urban, DL Rimm, H Fritsche,  J Gray, R Veltri, G Klee, A Allen,  N Kim, S Gutman, M.A. Rubin and A Hruszkewycz.  Translational Crossroads for Biomarkers. Clin. Cancer Res. 2005; 11: 6103-6108.
  65. Veltri, RW. MOLECULAR BIOLOGY OF SERUM BIOMARKERS FOR PROSTATE CANCER. In: Chapter 27, pp269-84.  Prostate Cancer: Principles and Practice, Edited by Roger Kirby, Alan Partin, Mark Feneley and J. Kellogg Parsons; 2006; Taylor and Francis Medical Books, Abingdon, OX14 4RN.
  66. Shiff C, Veltri R, Naples J, Quartey J, Otchere J, Anyan W, Marlow C, Wiredu E, Adjei A, Brakohiapa E, Bosompem K.  Ultrasound verification of bladder damage is associated with known biomarkers of bladder cancer in adults chronically infected with Schistosoma haematobium infection in Ghana. Trans. R. Soc. Trop. Med. Hyg. 2006; 100: 847-854.
  67. Veltri RW. Editorial comment. J Urol. 2006 Mar; 175(3): 944.
  68. Lee R, Localio R, Armstrong K, Malkowicz B, Schwartz JS, and The Free PSA Study Group. A Meta-Analysis of the Performance Characteristics of the Free Prostate-Specific Antigen Test. Urology 2006; 67: 762–768. [A total of 5401 subjects from our publication Urology 1999; 53: 736-754]
  69. Nielsen, ME, Schaeffer EM, Veltri RW, Schoenberg MP and Getzenberg RH. Urinary Markers in the Detection of Bladder Cancer - What’s New? Curr Opin Urol Rev.  2006; 16: 350-355.
  70. Parwani AV, Marlow C, DeMarzo A, Mikolajczyk SD, Rittenhouse HG, Veltri RW and Chan TY. Immunochemical Staining of Precursor Forms of Prostate cancer Antigen (ProPSA) in Metastatic Prostate cancer. Am J Surg Pathol. 2006; 10:1231-1236.
  71. Veltri RW, Khan MA, Marlow C, Miller MC, Mikolajczyk SD, Kojima M, Partin AW, Marks LS. Alterations in Nuclear Structure and Expression of ProPSA Predict Differences Between Native Japanese and Japanese American Prostate Cancer. Urology,2006; 68: 898-904.
  72. Veltri RW and Makarov DV. Nucleic Acid-Based Marker Approaches to Urologic Cancers. In: Seminars in Urologic Oncology, “Molecular Markers of Urologic Cancers", Ed. Robert G. Getzenberg, Elsevier, Philadelphia, PA. 2006; 24: 510-527.
  73. Marks LS, Mazer NA, Mostaghel E, Hess DL, Dorey FJ, Epstein JI, Veltri RW, Makarov DV, Partin AW, Bostwick DG, Macairan ML, Nelson PS. Effect of Testosterone Replacement Therapy on Prostate Tissue in Men With Late-Onset Hypogonadism: A Randomized Controlled Trial. JAMA. 2006 Nov 15; 296(19):2351-2361.
  74. Veltri RW and Rodriguez R.  Campbell-Walsh Urology 9th Edition. Editor-in-Chief, Alan J. Wein, M.D., Ph.D (Hon). Eds. Kavoussi, LR, Novick AC, Partin AW, and Peters CA. Chapter 85,Vol 3; p2677-2726, Molecular Biology, endocrinology, and physiology of the prostate and seminal vesicles. Saunders-Elsevier, 170 S Independence Mall W, Suite 300E; Philadelphia, PA.
  75. Veltri RW, Marlow C, Khan MA, Michael C. Miller MC, Epstein JI, and Partin AW. Significant Variations in Nuclear Structure Occur Between and Within Gleason Grading Patterns 3, 4, and 5 Determined by Digital Image Analysis. The Prostate. May 2007; 67(11):1202-1210.
  76. Malik G, Rojahn E, Ward MD, Gretzer MB, Partin AW, Semmes OJ, Veltri RW.  SELDI protein profiling of dunning R-3327 derived cell lines: Identification of molecular markers of prostate cancer progression.  The Prostate. 2007; 67(14):1565-1575.
  77. Chuang AY, DeMarzo AM, Veltri RW, Sharma RB, Bieberich CJ, Epstein JI. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma.  Am J Surg Pathol. 2007; 31(8):1246-55.
  78. Kelloff GJ, Sullivan DC, Baker H, Clarke LP, Nordstrom R, Tatum JL, Dorfman GS, Jacobs P, Berg CD, Pomper MG, Birrer MJ, Tempero M, Higley HR, Petty BG, Sigman CC, Maley C, Sharma P, Wax A, Ginsberg GG, Dannenberg AJ, Hawk ET, Messing EM, Grossman HB, Harisinghani M, Bigio IJ, Griebel D, Henson DE, Fabian CJ, Ferrara K, Fantini S, Schnall MD, Zujewski JA, Hayes W, Klein EA, DeMarzo A, Ocak I, Ketterling JA, Tempany C, Shtern F, Parnes HL, Gomez J, Srivastava S, Szabo E, Lam S, Seibel EJ, Massion P, McLennan G, Cleary K, Suh R, Burt RW, Pfeiffer RM, Hoffman JM, Roy HK, Wang T, Limburg PJ, El-Deiry WS, Papadimitrakopoulou V, Hittelman WN, MacAulay C, Veltri RW, Solomon D, Jeronimo J, Richards-Kortum R, Johnson KA, Viner JL, Stratton SP, Rajadhyaksha M, Dhawan A; Workshop Program Committee. Workshop on imaging science development for cancer prevention and preemption. Cancer Biomarkers, 2007; 3(1):1-33.
  79. Makarov DV, Marlow C, Epstein JI, M. Miller MC, Landis P, Partin AW, Carter HB, and Veltri RW.  Predicting the Need for Treatment among Men with Low Grade, Low Stage Prostate Cancer Enrolled in a Program of Expectant Management with Curative Intent. The Prostate, 2008; 68:183 -189.
  80. Veltri RW, Ph.D., Miller MC, Isharwal S, Marlow C, BS., Makarov DV M.D., B.S and Partin AW, M.D., PhD. Prediction of PSA Recurrence in Men with 12 years Post-prostatectomy Follow-up.  Cancer Epidemiology Biomarkers Prev, 2008; 17(1):102– 110.
  81. Isharwal S, Miller MC, Marlow C, Makarov DV, Partin AW and Veltri RW. p300 (Histone Acetyltransferase) Biomarker Predicts Prostate Cancer Biochemical Recurrence and Correlates with Changes in Epithelia Nuclear Size and Shape. The Prostate, 2008; 68(10):1097-104.
  82. Isharwal S, Miller MC, B.S., Epstein JI, Mangold LA., Humphreys E, Partin AW, Veltri RW. Prognostic value of Her-2/neu and %DNA Index for Progression, Metastasis and Prostate Cancer-specific Death in Men with Long-Term Follow-up after Radical Prostatectomy. Submitted: Int. J Cancer, April 2008;123, 2636–2643 (2008).
  83. Veltri RW, Isharwal S, Miller MC, Epstein JI, Mangold, LA, Humphreys E, and Partin AW. Long-Term Assessment of Prostate Cancer Progression Free Survival: Evaluation of Pathological Parameters, Nuclear Shape and Molecular Biomarkers of Pathogenesis. Received 5 June 2008; Accepted 31 July 2008; DOI 10.1002/pros.20848.
  84. Isharwal S, Miller MC, B.S., Epstein JI, Mangold LA., Humphreys E, Partin AW, Veltri RW. Nuclear DNA Ploidy Measurements as a Surrogate to Biopsy Gleason Score for Preoperative Pathologic Stage Prediction. Submitted: Urology, Accepted 10-08-08 (In Press).
  85. Naples J, Isharwal S, Shiff C, Bosompem KM, and Veltri RW.  Clinical Utility of Squamous and Transitional Nuclear Structure Alterations induced by Schistosoma haematobium in chronically infected adults with bladder damage verified by Ultrasound in Ghana.  AQCH, 2008; Accepted 10-27-08 (In Press).
  86. Hu R, Dunn TA, Wei S, Isharwal S, Veltri RW, Humphrey E, Han M, Partin AW, DeMarzo AM, Isaacs WB, Bova GS, and Luo J.  Ligand-independent Androgen Receptor Variants Derived from Splicing of Cryptic Exons Signify Hormone Refractory Prostate Cancer. Cancer Res, 2009; 69: (1); 1-7. January 1, 2009; Accepted 10-29-08. (In Press).
  87. Kortenhorst MSQ, Isharwal S, van Diest PJ, Chowdhury WH, Marlow C, Carducci MA, Rodriguez R, Veltri RW. Valproic acid causes dose- and time-dependent changes in nuclear structure in prostate cancer cells in vitro and in vivo.  Mol Cancer Ther. 2009; 8(4): 802–808.
  88. Isharwal S, Makarov DV, Carter HB, Epstein JI, Partin AW, Landis P, Marlow C, and Veltri RW.  DNA content in the diagnostic biopsy benign-adjacent and cancer tissue areas predicts the need for treatment in men with T1c prostate cancer undergoing surveillance in an expectant management program.  B JUI, 105, 2009; 329 – 333.
  89. Shiff C, Naples JM, Isharwal S, Bosompem KM, and Veltri RW. Non-invasive methods to detect schistosome-based bladder cancer: is the association sufficient? Trans R Soc Trop Med Hyg. 2010 Jan;104(1):3-5.
  90. Makarov DV, Isharwal S, Sokoll LJ, Marlow C, Epstein JI, Partin AW, Carter HB, and Veltri RW. proPSA Measurements in Serum and Tissue are Associated with Treatment Necessity Among Men Enrolled in Expectant Management for Prostate Cancer.  Clin Cancer Res 2009; 15(23):7316–21.
  91. Veltri RW, Isharwal S, Miller MC Epstein JI, and Partin AW. Nuclear Roundness Variance predicts
    Prostate Cancer Progression, Metastasis and Death: A prospective evaluation with up to 25 years of Follow-up after Radical Prostatectomy. The Prostate, 2010; 70: 1333–1339.
  92. Huang Y, Isharwal S, Haese A, Chun FK, Makarov DV, Feng Z, Han M, Humphreys E, Epstein JI, Partin AW and Veltri RW: Prediction of Patient-specific risk and percentile cohort risk of pathological stage using continuous PSA measurement, clinical stage and biopsy Gleason score. BJU Int. 2011 May ; 107(10): 1562–1569.
  93. Isharwal S, Makarov DV, Sokoll L, Landis P, Marlow C, Epstein JI, Partin AW, Carter HB, and Veltri RW: proPSA and diagnostic biopsy tissue DNA content combination improves accuracy to predict the need for prostate cancer treatment among men enrolled in a proactive surveillance program.  Urology, 2011; 77(3):763.e1-6.
  94. Ali S, Veltri R, Epstein JI, Christudass C, Madabhushi A: Adaptive Energy Selective Active Contour with Shape Priors for Nuclear Segmentation and Gleason Grading of Prostate Cancer. MICCAI (1) 2011: 661-669.
  95. Tosoian JJ, Loeb S, Isharwal S, Landis P, Elliot DJ, Feng Z, Veltri R,  Epstein JI, Partin AW, Trock B, H. Carter B and Sokoll LJ.  [-2] proPSA is Associated with Biopsy Reclassification in Men on Active Surveillance for Prostate Cancer. Accepted for J Urology, 2012; 188: 1131-36.
  96. Veltri RW, Christudass CS, and Isharwal S. Nuclear morphometry, nucleomics and prostate cancer progression. Asian J Androl. 2012 May;14 (3):375-84. doi: 10.1038/aja.2011.148.
  97. Carter HB, Partin AW, Walsh PC, Trock BJ, Veltri RW, Nelson WG, Coffey DS, Singer EA, Epstein JI. Gleason Score 6 Adenocarcinoma: Should It Be Labeled As Cancer? J Clin Oncol. 2012 Oct 1. [Epub ahead of print]
  98. Kim JJ, Bo Yin B, Christudass CS, Terada N, Rajagopalan K, Fabry B, Danielle Y. Lee DY, Shiraishi T, Robert H. Getzenberg  RH,  Veltri1 RW, An SS, & Mooney SM. Acquisition of paclitaxel resistance is associated with a more aggressive and invasive phenotype in prostate cancer. J Cellular Biochemistry, J Cell Biochem. 2012 Nov 28. doi: 10.1002/jcb.24464. [Epub ahead of print]
  99. Zhong, X, Isharwal, S. Naples, JM, Shiff, C, Veltri, RW, Shao, C, Bosompem K, Sidransky, D and Hoque, MO. Hypermethylation of genes detected in urine from Ghanaian adults with bladder pathology associated with Schistosoma Haematobium infection. PLoS One. 2013; 8(3):e59089. doi: 10.1371/journal.pone.0059089. Epub 2013 Mar 18. PMID:  23527093.
  100. Ali S, Veltri R, Epstein JI, Christudass C, Madabhushi A. Cell Cluster Graph for Prediction of Biochemical Recurrence in Prostate Cancer Patients from Tissue Microarrays. Proc of SPIE Vol. 8676, 86760H-1.  doi: 10.1117/12.2008695
  101. Wei Y, Zou Z, Becker N, Anderson M, Sumpter R, Xiao G, Kinch L, Koduru P, Christudass CS, Veltri RW, Grishin NV, Peyton M, Minna J, Bhagat G, Levine B. EGFR-mediated Beclin 1 phosphorylation in autophagy suppression, tumor progression, and tumor chemoresistance. Cell. 2013 Sep 12;154(6):1269-84. doi: 10.1016/j.cell.2013.08.015.
  102. Lee G, Ali S, Veltri RW, Epstein JI, Christudass C, and Madabhushi A. Cell Orientation Entropy (COrE): Predicting Biochemical Recurrence from Prostate Cancer Tissue Microarrays. MICCAI, Sep. 22-26, 2013, Nagoya, Japan.
  103. Veltri RW and Christudass CS. Nuclear morphometry, epigenetic changes, and clinical relevance in prostate cancer.  Adv Exp Med Biol. 2014; 733: 77-99. doi: 10.1007/978-14899-8032-8 4. PMID: 2453344 [PubMed – in process]
  104. Kianercy A, Veltri RW, Pienta KJ. Critical transitions in a game theoretic model of tumour metabolism. Journal of the Royal Society Interface Focus, 2014; 
  105. Veltri RW, Ph.D., Guangjing Zhu G, Lee G, Ali S, M.S., Madabhushi A. Histomorphometry of Digital Pathology: Case Study in Prostate Cancer. Frontiers of Medical Imaging, edited by C.H. Chen. 2014 (in process).
  106. Tian Y, Choi CH, Li QK, Rahmatpanah FB, Chen X, Kim SR, Veltri RW, Chia D, Zhang Z, Kagan J, Dan Mercola, Zhang H. Overexpression of periostin in stroma positively associated with aggressive prostate cancer. A multi-institution study. PLOSone, submitted September, 2014.
  107. Verdone J, Princy P, Veltri RW, Pienta K. Epithelial-mesenchymal transition in prostate cancer is associated with quantifiable changes in nuclear structure. The Prostate;. Accepted 8-25-14.
  108. Ali  S, Veltri R, Epstein JI, Christhunesa Christudass CS, Madabhushi A. Selective Invocation of Shape Priors for Deformable Segmentation and Morphologic Classification of Prostate Cancer Tissue Microarrays. CMIG, December, 2014.
  109. Veltri RW. Non-coding RNAs as biomarkers for metastatic prostate cancer. The Lancet Oncology, Volume 15, Issue 13, Pages 1412 - 1413, December 2014. doi:10.1016/S1470-2045(14)71124-6

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.| Disclaimer
Email: | 600 North Wolfe Street, Baltimore, Maryland 21287